TrialFrontiers in immunology2022

Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy.

Lin Jia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.